id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
APHIS-2023-0088-0001,APHIS,APHIS-2023-0088,Payment of Indemnity and Compensation for Highly Pathogenic Avian Influenza,Rule,Interim Final Rule,2024-12-31T05:00:00Z,2024,12,2024-12-31T05:00:00Z,2025-03-04T04:59:59Z,2025-03-14T01:00:15Z,2024-31384,0,0,0900006486896c83
APHIS-2022-0061-0004,APHIS,APHIS-2022-0061,US SHIP Program Standards,Supporting & Related Material,Guidance,2024-12-31T05:00:00Z,2024,12,,,2024-12-31T14:13:38Z,,0,0,0900006486888ffb
APHIS-2022-0061-0001,APHIS,APHIS-2022-0061,U.S. Swine Health Improvement Plan,Proposed Rule,Notice of Proposed Rulemaking (NPRM),2024-12-31T05:00:00Z,2024,12,2024-12-31T05:00:00Z,2025-04-01T03:59:59Z,2025-04-02T01:00:43Z,2024-31386,0,0,0900006486896dc1
APHIS-2023-0088-0004,APHIS,APHIS-2023-0088,Biosecurity Audit Tool,Supporting & Related Material,Supplement,2024-12-31T05:00:00Z,2024,12,,,2024-12-31T14:16:16Z,,0,0,090000648688880f
APHIS-2022-0061-0002,APHIS,APHIS-2022-0061,PRA Abstract,Supporting & Related Material,Paperwork Packages,2024-12-31T05:00:00Z,2024,12,,,2024-12-31T14:13:21Z,,0,0,0900006486888ffd
APHIS-2023-0088-0003,APHIS,APHIS-2023-0088,Information Collection Abstract,Supporting & Related Material,Paperwork Packages,2024-12-31T05:00:00Z,2024,12,,,2024-12-31T14:16:11Z,,0,0,0900006486888a96
APHIS-2023-0088-0002,APHIS,APHIS-2023-0088,Initial Regulatory Flexibility Analysis (Economic Analysis),Supporting & Related Material,Economic Analysis,2024-12-31T05:00:00Z,2024,12,,,2024-12-31T14:16:02Z,,0,0,0900006486888ffa
APHIS-2022-0061-0003,APHIS,APHIS-2022-0061,Initial Economic Analysis,Supporting & Related Material,Economic Analysis,2024-12-31T05:00:00Z,2024,12,,,2024-12-31T14:13:32Z,,0,0,0900006486888ffc
EPA-HQ-OPPT-2024-0501-0001,EPA,EPA-HQ-OPPT-2024-0501,Preliminary Lists Identifying Manufacturers Subject to Fee Obligations for Five Chemical Substances Undergoing EPA-Initiated Risk Evaluations Under the Toxic Substances Control Act (TSCA); Determination; Notice of Availability and Request for Comment,Proposed Rule,,2024-12-31T05:00:00Z,2024,12,2024-12-31T05:00:00Z,2025-03-04T04:59:59Z,2025-03-01T02:00:28Z,2024-30930,0,0,0900006486896ad6
EPA-HQ-OPPT-2024-0501-0003,EPA,EPA-HQ-OPPT-2024-0501,"High-Priority Substance Designations Under the Toxic Substances Control Act (TSCA) and Initiation of Risk Evaluation on High-Priority Substances; Notice of Availability, December 2024",Supporting & Related Material,Publication - Previous/Related FR Notice,2024-12-31T05:00:00Z,2024,12,,,2025-01-01T01:45:59Z,,0,0,090000648687c2b9
EPA-HQ-OPPT-2024-0501-0007,EPA,EPA-HQ-OPPT-2024-0501,"Preliminary List Identifying Manufacturers Subject to Fee Obligations for EPA-Initiated Risk Evaluations of Chemical, 4,4′-Methylene bis(2-chloroaniline) (MBOCA), CAS #: 101-14-4",Supporting & Related Material,Data,2024-12-31T05:00:00Z,2024,12,,,2025-01-01T01:47:04Z,,0,0,090000648687c2f9
EPA-R09-OAR-2024-0633-0001,EPA,EPA-R09-OAR-2024-0633,Receipt of Tribal Minor NSR Permit Application for Ratherford Unit WIP Mud Plant,Notice,,2024-12-31T05:00:00Z,2024,12,2024-12-31T05:00:00Z,,2025-01-01T01:53:57Z,,0,0,09000064868974b8
EPA-R09-OW-2023-0623-0104,EPA,EPA-R09-OW-2023-0623,R9UIC_CA6_FY22_1.4 Final Permit 12.30.2024,Other,,2024-12-31T05:00:00Z,2024,12,2024-12-31T05:00:00Z,,2025-01-01T01:54:26Z,,0,0,090000648689624e
EPA-HQ-OPPT-2024-0501-0004,EPA,EPA-HQ-OPPT-2024-0501,"Fees for the Administration of the Toxic Substances Control Act Final Rule, October 2018",Supporting & Related Material,Publication - Previous/Related FR Notice,2024-12-31T05:00:00Z,2024,12,,,2025-01-01T01:45:46Z,,0,0,090000648687c2ba
EPA-HQ-OPPT-2024-0501-0005,EPA,EPA-HQ-OPPT-2024-0501,"Initiation of Prioritization Under the Toxic Substances Control Act (TSCA); Request for Comment, December 2023",Supporting & Related Material,Publication - Previous/Related FR Notice,2024-12-31T05:00:00Z,2024,12,,,2025-01-01T01:47:30Z,,0,0,090000648687c2bb
EPA-R09-OAR-2023-0649-0011,EPA,EPA-R09-OAR-2023-0649,Air Quality State Implementation Plans; Approvals and Promulgations: California; Feather River Air Quality Management District,Rule,,2024-12-31T05:00:00Z,2024,12,2024-12-31T05:00:00Z,,2025-01-02T16:12:57Z,2024-31396,0,0,0900006486896c3c
EPA-R09-OW-2023-0623-0106,EPA,EPA-R09-OW-2023-0623,R9UIC_CA6_FY22_1.2 Final Permit 12.30.2024,Other,,2024-12-31T05:00:00Z,2024,12,2024-12-31T05:00:00Z,,2025-01-01T01:55:30Z,,0,0,0900006486896584
EPA-HQ-OPPT-2024-0501-0009,EPA,EPA-HQ-OPPT-2024-0501,"Preliminary List Identifying Manufacturers Subject to Fee Obligations for EPA-Initiated Risk Evaluations of Chemical, Benzenamine, CAS #: 62-53-3",Supporting & Related Material,Data,2024-12-31T05:00:00Z,2024,12,,,2025-01-01T01:46:38Z,,0,0,090000648687c2fb
EPA-R09-OW-2023-0623-0108,EPA,EPA-R09-OW-2023-0623,Notice of final permit decision - CTV I 26R (12.30.24),Notice,,2024-12-31T05:00:00Z,2024,12,2024-12-31T05:00:00Z,,2025-01-01T01:54:09Z,,0,0,090000648689625d
EPA-R09-OAR-2024-0632-0001,EPA,EPA-R09-OAR-2024-0632,Receipt of Tribal Minor NSR Permit Application for McElmo Creek Unit Area 4 Tank Battery,Notice,,2024-12-31T05:00:00Z,2024,12,2024-12-31T05:00:00Z,,2025-01-01T01:53:43Z,,0,0,09000064868974b6
EPA-R09-OW-2023-0623-0105,EPA,EPA-R09-OW-2023-0623,R9UIC_CA6_FY22_1.3 Final Permit 12.30.2024,Other,,2024-12-31T05:00:00Z,2024,12,2024-12-31T05:00:00Z,,2025-01-01T01:55:12Z,,0,0,0900006486896243
EPA-HQ-OPPT-2024-0501-0002,EPA,EPA-HQ-OPPT-2024-0501,"Fees for the Administration of the Toxic Substances Control Act (TSCA) Final Rule, February 2024",Supporting & Related Material,Publication - Previous/Related FR Notice,2024-12-31T05:00:00Z,2024,12,,,2025-01-01T01:46:12Z,,0,0,090000648687c2b8
EPA-HQ-OPPT-2024-0501-0008,EPA,EPA-HQ-OPPT-2024-0501,"Preliminary List Identifying Manufacturers Subject to Fee Obligations for EPA-Initiated Risk Evaluations of Chemical, Acrylonitrile, CAS #: 107-13-1",Supporting & Related Material,Data,2024-12-31T05:00:00Z,2024,12,,,2025-01-01T01:47:17Z,,0,0,090000648687c2fa
EPA-R09-OW-2023-0623-0109,EPA,EPA-R09-OW-2023-0623,Response to Comments CTV-I 26R (12.30.24),Supporting & Related Material,,2024-12-31T05:00:00Z,2024,12,,,2025-01-01T01:54:39Z,,0,0,090000648689625e
EPA-HQ-OPPT-2024-0501-0006,EPA,EPA-HQ-OPPT-2024-0501,"Preliminary List Identifying Manufacturers Subject to Fee Obligations for EPA-Initiated Risk Evaluations of Chemical, Acetaldehyde, CAS #: 75-07-0",Supporting & Related Material,Data,2024-12-31T05:00:00Z,2024,12,,,2025-01-01T01:46:25Z,,0,0,090000648687c2f8
EPA-R09-OW-2023-0623-0107,EPA,EPA-R09-OW-2023-0623,R9UIC_CA6_FY22_1.1 Final Permit 12.30.2024,Other,,2024-12-31T05:00:00Z,2024,12,2024-12-31T05:00:00Z,,2025-01-01T01:54:56Z,,0,0,0900006486896564
EPA-HQ-OPPT-2024-0501-0010,EPA,EPA-HQ-OPPT-2024-0501,"Preliminary List Identifying Manufacturers Subject to Fee Obligations for EPA-Initiated Risk Evaluations of Chemical, Vinyl Chloride, CAS #: 75-01-4",Supporting & Related Material,Data,2024-12-31T05:00:00Z,2024,12,,,2025-01-01T01:46:51Z,,0,0,090000648687c2fc
FDA-2022-N-2390-0097,FDA,FDA-2022-N-2390,Exhibit 208,Supporting & Related Material,Background Material,2024-12-31T05:00:00Z,2024,12,,,2025-04-04T15:29:54Z,,0,0,09000064868a2ef0
FDA-2022-N-2390-0128,FDA,FDA-2022-N-2390,Exhibit 239,Supporting & Related Material,Background Material,2024-12-31T05:00:00Z,2024,12,,,2025-04-04T15:26:26Z,,0,0,09000064868a2f37
FDA-2022-N-2390-0123,FDA,FDA-2022-N-2390,Exhibit 234,Supporting & Related Material,Background Material,2024-12-31T05:00:00Z,2024,12,,,2025-04-04T15:26:56Z,,0,0,09000064868a2f32
FDA-2022-N-2390-0126,FDA,FDA-2022-N-2390,Exhibit 237,Supporting & Related Material,Background Material,2024-12-31T05:00:00Z,2024,12,,,2025-04-04T15:26:37Z,,0,0,09000064868a2f35
FDA-2022-N-2390-0090,FDA,FDA-2022-N-2390,Exhibit 201,Supporting & Related Material,Background Material,2024-12-31T05:00:00Z,2024,12,,,2025-04-04T15:29:04Z,,0,0,09000064868a2ee9
FDA-2022-N-2390-0096,FDA,FDA-2022-N-2390,Exhibit 207,Supporting & Related Material,Background Material,2024-12-31T05:00:00Z,2024,12,,,2025-04-04T15:29:48Z,,0,0,09000064868a2eef
FDA-2022-N-2390-0127,FDA,FDA-2022-N-2390,Exhibit 238,Supporting & Related Material,Background Material,2024-12-31T05:00:00Z,2024,12,,,2025-04-04T15:26:31Z,,0,0,09000064868a2f36
FDA-2022-N-2390-0088,FDA,FDA-2022-N-2390,Exhibit 199,Supporting & Related Material,Background Material,2024-12-31T05:00:00Z,2024,12,,,2025-04-04T15:28:52Z,,0,0,09000064868a3103
FDA-2022-N-2390-0103,FDA,FDA-2022-N-2390,Exhibit 214,Supporting & Related Material,Background Material,2024-12-31T05:00:00Z,2024,12,,,2025-04-04T15:32:27Z,,0,0,09000064868a2f07
FDA-2022-N-2390-0115,FDA,FDA-2022-N-2390,Exhibit 226,Supporting & Related Material,Background Material,2024-12-31T05:00:00Z,2024,12,,,2025-04-04T15:31:14Z,,0,0,09000064868a2f1d
FDA-2022-N-2390-0101,FDA,FDA-2022-N-2390,Exhibit 212,Supporting & Related Material,Background Material,2024-12-31T05:00:00Z,2024,12,,,2025-04-04T15:32:37Z,,0,0,09000064868a2f05
FDA-2022-N-2390-0107,FDA,FDA-2022-N-2390,Exhibit 218,Supporting & Related Material,Background Material,2024-12-31T05:00:00Z,2024,12,,,2025-04-04T15:32:05Z,,0,0,09000064868a2f0b
FDA-2022-N-2390-0120,FDA,FDA-2022-N-2390,Exhibit 231,Supporting & Related Material,Background Material,2024-12-31T05:00:00Z,2024,12,,,2025-04-04T15:30:47Z,,0,0,09000064868a2f2f
FDA-2024-H-5929-0001,FDA,FDA-2024-H-5929,Complaint,Other,Complaint,2024-12-31T05:00:00Z,2024,12,2025-01-02T05:00:00Z,,2025-01-02T14:32:14Z,,0,0,090000648689709d
FDA-2000-N-0011-0028,FDA,FDA-2000-N-0011,Uniform Compliance Date for Food Labeling Regulations,Rule,Final Rule,2024-12-31T05:00:00Z,2024,12,2024-12-31T05:00:00Z,2025-03-04T04:59:59Z,2025-03-05T02:00:44Z,2024-31419,0,0,0900006486896c8a
FDA-2024-N-3271-0002,FDA,FDA-2024-N-3271,Flamingo Pharmaceuticals Ltd.; Withdrawal of Approval of Two Abbreviated New Drug Applications,Notice,Withdrawal,2024-12-31T05:00:00Z,2024,12,2024-12-31T05:00:00Z,,2024-12-31T14:36:36Z,2024-31360,0,0,0900006486896c82
FDA-2024-H-5921-0001,FDA,FDA-2024-H-5921,Complaint,Other,Complaint,2024-12-31T05:00:00Z,2024,12,2024-12-31T05:00:00Z,,2024-12-31T16:08:58Z,,0,0,090000648689712d
FDA-2022-N-2390-0105,FDA,FDA-2022-N-2390,Exhibit 216,Supporting & Related Material,Background Material,2024-12-31T05:00:00Z,2024,12,,,2025-04-04T15:32:18Z,,0,0,09000064868a2f09
FDA-2022-N-2390-0106,FDA,FDA-2022-N-2390,Exhibit 217,Supporting & Related Material,Background Material,2024-12-31T05:00:00Z,2024,12,,,2025-04-04T15:32:11Z,,0,0,09000064868a2f0a
FDA-2022-N-2390-0111,FDA,FDA-2022-N-2390,Exhibit 222,Supporting & Related Material,Background Material,2024-12-31T05:00:00Z,2024,12,,,2025-04-04T15:31:39Z,,0,0,09000064868a2f19
FDA-2022-N-2390-0113,FDA,FDA-2022-N-2390,Exhibit 224,Supporting & Related Material,Background Material,2024-12-31T05:00:00Z,2024,12,,,2025-04-04T15:31:26Z,,0,0,09000064868a2f1b
FDA-2022-N-2390-0079,FDA,FDA-2022-N-2390,Exhibit 190,Supporting & Related Material,Background Material,2024-12-31T05:00:00Z,2024,12,,,2025-04-04T15:27:08Z,,0,0,09000064868a27cf
FDA-2022-N-2390-0084,FDA,FDA-2022-N-2390,Exhibit 195,Supporting & Related Material,Background Material,2024-12-31T05:00:00Z,2024,12,,,2025-04-04T15:28:11Z,,0,0,09000064868a28ff
FDA-2022-N-2390-0098,FDA,FDA-2022-N-2390,Exhibit 209,Supporting & Related Material,Background Material,2024-12-31T05:00:00Z,2024,12,,,2025-04-04T15:29:59Z,,0,0,09000064868a2ef1
FDA-2022-N-2390-0074,FDA,FDA-2022-N-2390,Index to Exhibits,Supporting & Related Material,Background Material,2024-12-31T05:00:00Z,2024,12,,,2025-04-04T15:25:42Z,,0,0,09000064868a4593
FDA-2022-N-2390-0080,FDA,FDA-2022-N-2390,Exhibit 191,Supporting & Related Material,Background Material,2024-12-31T05:00:00Z,2024,12,,,2025-04-04T15:27:13Z,,0,0,09000064868a28fb
FDA-2024-H-5925-0001,FDA,FDA-2024-H-5925,Complaint,Other,Complaint,2024-12-31T05:00:00Z,2024,12,2025-01-02T05:00:00Z,,2025-01-02T14:58:24Z,,0,0,090000648689756a
FDA-2024-H-5800-0001,FDA,FDA-2024-H-5800,Complaint,Other,Complaint,2024-12-31T05:00:00Z,2024,12,2025-01-02T05:00:00Z,,2025-01-02T15:04:04Z,,0,0,0900006486898448
FDA-2024-H-5916-0001,FDA,FDA-2024-H-5916,Complaint,Other,Complaint,2024-12-31T05:00:00Z,2024,12,2025-01-02T05:00:00Z,,2025-01-02T15:11:03Z,,0,0,0900006486898d43
FDA-2024-H-5928-0001,FDA,FDA-2024-H-5928,Complaint,Other,Complaint,2024-12-31T05:00:00Z,2024,12,2025-01-02T05:00:00Z,,2025-01-02T14:04:26Z,,0,0,0900006486897071
FDA-2024-H-5920-0001,FDA,FDA-2024-H-5920,Complaint,Other,Complaint,2024-12-31T05:00:00Z,2024,12,2024-12-31T05:00:00Z,,2024-12-31T15:13:15Z,,0,0,09000064868968ce
FDA-2024-H-5922-0001,FDA,FDA-2024-H-5922,Complaint,Other,Complaint,2024-12-31T05:00:00Z,2024,12,2024-12-31T05:00:00Z,,2024-12-31T15:54:19Z,,0,0,0900006486897104
FDA-2024-N-2980-0006,FDA,FDA-2024-N-2980,"Evaluating the Immunogenicity Risk of Host Cell Proteins in Follow-On Recombinant Peptide Products;
Reopening of the Comment Period",Notice,Extension of Comment Period,2024-12-31T05:00:00Z,2024,12,2024-12-31T05:00:00Z,,2024-12-31T14:48:35Z,2024-31365,0,0,0900006486896ad4
FDA-2024-H-5924-0001,FDA,FDA-2024-H-5924,Complaint,Other,Complaint,2024-12-31T05:00:00Z,2024,12,2025-01-02T05:00:00Z,,2025-01-02T14:57:26Z,,0,0,090000648689754d
FDA-2022-N-2390-0085,FDA,FDA-2022-N-2390,Exhibit 196,Supporting & Related Material,Background Material,2024-12-31T05:00:00Z,2024,12,,,2025-04-04T15:28:17Z,,0,0,09000064868a3100
FDA-2022-N-2390-0100,FDA,FDA-2022-N-2390,Exhibit 211,Supporting & Related Material,Background Material,2024-12-31T05:00:00Z,2024,12,,,2025-04-04T15:30:11Z,,0,0,09000064868a2f04
FDA-2022-N-2390-0102,FDA,FDA-2022-N-2390,Exhibit 213,Supporting & Related Material,Background Material,2024-12-31T05:00:00Z,2024,12,,,2025-04-04T15:32:32Z,,0,0,09000064868a2f06
FDA-2022-N-2390-0104,FDA,FDA-2022-N-2390,Exhibit 215,Supporting & Related Material,Background Material,2024-12-31T05:00:00Z,2024,12,,,2025-04-04T15:32:23Z,,0,0,09000064868a2f08
FDA-2022-N-2390-0112,FDA,FDA-2022-N-2390,Exhibit 223,Supporting & Related Material,Background Material,2024-12-31T05:00:00Z,2024,12,,,2025-04-04T15:31:32Z,,0,0,09000064868a2f1a
FDA-2022-N-2390-0114,FDA,FDA-2022-N-2390,Exhibit 225,Supporting & Related Material,Background Material,2024-12-31T05:00:00Z,2024,12,,,2025-04-04T15:31:20Z,,0,0,09000064868a2f1c
FDA-2022-N-2390-0117,FDA,FDA-2022-N-2390,Exhibit 228,Supporting & Related Material,Background Material,2024-12-31T05:00:00Z,2024,12,,,2025-04-04T15:31:03Z,,0,0,09000064868a2f1f
FDA-2024-H-5931-0001,FDA,FDA-2024-H-5931,Complaint,Other,Complaint,2024-12-31T05:00:00Z,2024,12,2025-01-02T05:00:00Z,,2025-01-02T14:48:56Z,,0,0,09000064868971c7
FDA-2024-H-5917-0001,FDA,FDA-2024-H-5917,Complaint,Other,Complaint,2024-12-31T05:00:00Z,2024,12,2025-01-02T05:00:00Z,,2025-01-02T15:11:54Z,,0,0,0900006486898d49
FDA-2022-N-2390-0083,FDA,FDA-2022-N-2390,Exhibit 194,Supporting & Related Material,Background Material,2024-12-31T05:00:00Z,2024,12,,,2025-04-04T15:27:40Z,,0,0,09000064868a28fe
FDA-2022-N-2390-0094,FDA,FDA-2022-N-2390,Exhibit 205,Supporting & Related Material,Background Material,2024-12-31T05:00:00Z,2024,12,,,2025-04-04T15:29:37Z,,0,0,09000064868a2eed
FDA-2022-N-2390-0089,FDA,FDA-2022-N-2390,Exhibit 200,Supporting & Related Material,Background Material,2024-12-31T05:00:00Z,2024,12,,,2025-04-04T15:28:58Z,,0,0,09000064868a3104
FDA-2022-N-2390-0075,FDA,FDA-2022-N-2390,Exhibit 186,Supporting & Related Material,Background Material,2024-12-31T05:00:00Z,2024,12,,,2025-04-04T15:25:49Z,,0,0,09000064868a27cb
FDA-2022-N-2390-0076,FDA,FDA-2022-N-2390,Exhibit 187,Supporting & Related Material,Background Material,2024-12-31T05:00:00Z,2024,12,,,2025-04-04T15:25:55Z,,0,0,09000064868a27cc
FDA-2022-N-2390-0099,FDA,FDA-2022-N-2390,Exhibit 210,Supporting & Related Material,Background Material,2024-12-31T05:00:00Z,2024,12,,,2025-04-04T15:30:05Z,,0,0,09000064868a2ef2
FDA-2022-N-2390-0124,FDA,FDA-2022-N-2390,Exhibit 235,Supporting & Related Material,Background Material,2024-12-31T05:00:00Z,2024,12,,,2025-04-04T15:26:49Z,,0,0,09000064868a2f33
FDA-2022-N-2390-0122,FDA,FDA-2022-N-2390,Exhibit 233,Supporting & Related Material,Background Material,2024-12-31T05:00:00Z,2024,12,,,2025-04-04T15:30:36Z,,0,0,09000064868a2f31
FDA-2022-N-2390-0109,FDA,FDA-2022-N-2390,Exhibit 220,Supporting & Related Material,Background Material,2024-12-31T05:00:00Z,2024,12,,,2025-04-04T15:31:53Z,,0,0,09000064868a2f0d
FDA-2024-H-5918-0001,FDA,FDA-2024-H-5918,Complaint,Other,Complaint,2024-12-31T05:00:00Z,2024,12,2024-12-31T05:00:00Z,,2024-12-31T14:00:47Z,,0,0,090000648689688b
FDA-2024-H-5867-0001,FDA,FDA-2024-H-5867,Complaint,Other,Complaint,2024-12-31T05:00:00Z,2024,12,2024-12-31T05:00:00Z,,2024-12-31T14:43:58Z,,0,0,09000064868968a8
FDA-2024-N-5830-0001,FDA,FDA-2024-N-5830,Advisory Committee; Dermatologic and Ophthalmic Drugs Advisory Committee; Renewal,Notice,Notice of Renewal,2024-12-31T05:00:00Z,2024,12,2024-12-31T05:00:00Z,,2024-12-31T14:00:03Z,2024-31363,0,0,0900006486896cc5
FDA-2024-H-5926-0001,FDA,FDA-2024-H-5926,Complaint,Other,Complaint,2024-12-31T05:00:00Z,2024,12,2025-01-02T05:00:00Z,,2025-01-02T14:59:14Z,,0,0,090000648689758c
FDA-2024-H-5915-0001,FDA,FDA-2024-H-5915,Complaint,Other,Complaint,2024-12-31T05:00:00Z,2024,12,2025-01-02T05:00:00Z,,2025-01-02T15:09:09Z,,0,0,09000064868984fb
FDA-2024-H-5832-0001,FDA,FDA-2024-H-5832,Complaint,Other,Complaint,2024-12-31T05:00:00Z,2024,12,2025-01-02T05:00:00Z,,2025-01-02T15:07:02Z,,0,0,090000648689844e
FDA-2022-N-2390-0086,FDA,FDA-2022-N-2390,Exhibit 197,Supporting & Related Material,Background Material,2024-12-31T05:00:00Z,2024,12,,,2025-04-04T15:28:27Z,,0,0,09000064868a3101
FDA-2022-N-2390-0092,FDA,FDA-2022-N-2390,Exhibit 203,Supporting & Related Material,Background Material,2024-12-31T05:00:00Z,2024,12,,,2025-04-04T15:29:18Z,,0,0,09000064868a2eeb
FDA-2022-N-2390-0095,FDA,FDA-2022-N-2390,Exhibit 206,Supporting & Related Material,Background Material,2024-12-31T05:00:00Z,2024,12,,,2025-04-04T15:29:43Z,,0,0,09000064868a2eee
FDA-2022-N-2390-0129,FDA,FDA-2022-N-2390,Exhibit 240,Supporting & Related Material,Background Material,2024-12-31T05:00:00Z,2024,12,,,2025-04-04T15:26:19Z,,0,0,09000064868a2f38
FDA-2022-N-2390-0093,FDA,FDA-2022-N-2390,Exhibit 204,Supporting & Related Material,Background Material,2024-12-31T05:00:00Z,2024,12,,,2025-04-04T15:29:32Z,,0,0,09000064868a2eec
FDA-2022-N-2390-0116,FDA,FDA-2022-N-2390,Exhibit 227,Supporting & Related Material,Background Material,2024-12-31T05:00:00Z,2024,12,,,2025-04-04T15:31:09Z,,0,0,09000064868a2f1e
FDA-2022-N-2390-0118,FDA,FDA-2022-N-2390,Exhibit 229,Supporting & Related Material,Background Material,2024-12-31T05:00:00Z,2024,12,,,2025-04-04T15:30:57Z,,0,0,09000064868a2f20
FDA-2022-N-2390-0110,FDA,FDA-2022-N-2390,Exhibit 221,Supporting & Related Material,Background Material,2024-12-31T05:00:00Z,2024,12,,,2025-04-04T15:31:47Z,,0,0,09000064868a2f18
FDA-2022-N-2390-0121,FDA,FDA-2022-N-2390,Exhibit 232,Supporting & Related Material,Background Material,2024-12-31T05:00:00Z,2024,12,,,2025-04-04T15:30:41Z,,0,0,09000064868a2f30
FDA-2024-H-5923-0001,FDA,FDA-2024-H-5923,Complaint,Other,Complaint,2024-12-31T05:00:00Z,2024,12,2024-12-31T05:00:00Z,,2024-12-31T16:22:10Z,,0,0,0900006486897134
FDA-2024-H-5919-0001,FDA,FDA-2024-H-5919,Complaint,Other,Complaint,2024-12-31T05:00:00Z,2024,12,2024-12-31T05:00:00Z,,2024-12-31T15:50:42Z,,0,0,09000064868968fe
FDA-2024-H-5930-0001,FDA,FDA-2024-H-5930,Complaint,Other,Complaint,2024-12-31T05:00:00Z,2024,12,2025-01-02T05:00:00Z,,2025-01-02T14:33:28Z,,0,0,090000648689751e
FDA-2024-H-5914-0001,FDA,FDA-2024-H-5914,Complaint,Other,Complaint,2024-12-31T05:00:00Z,2024,12,2025-01-02T05:00:00Z,,2025-01-02T15:08:06Z,,0,0,0900006486898496
FDA-2022-N-2390-0078,FDA,FDA-2022-N-2390,Exhibit 189,Supporting & Related Material,Background Material,2024-12-31T05:00:00Z,2024,12,,,2025-04-04T15:26:07Z,,0,0,09000064868a27ce
FDA-2022-N-2390-0091,FDA,FDA-2022-N-2390,Exhibit 202,Supporting & Related Material,Background Material,2024-12-31T05:00:00Z,2024,12,,,2025-04-04T15:29:10Z,,0,0,09000064868a2eea